by Nancy Lapid
(Reuters) – Here’s a summary of the latest scientific studies on the novel coronavirus. and efforts to find cures and vaccines for COVID-19, a viral disease.
New antibody drug shows promising prospect in mouse studies
A new experimental antibody drug from IGM Bioscience Inc may be more effective at suppressing the coronavirus and its variants than the current antibody therapy. Research in rats suggests And it is easier to deal with more direct effects on the lungs. Current antibody drugs use an antibody called IgG, which is bivalent (two arms), meaning it can attach itself to two spikes the coronavirus uses to penetrate cells simultaneously, says Zhiqiang An of Texas Medical Center. In Houston, and Pei-Yong Shi of the University of Texas Medical Branch at Galveston explain that the IgM antibody has 10 valence (10 weapons), so it can bind up to 10 spike proteins at the same time. One of the authors of the paper in Nature, IgM antibodies can bind to the virus more strongly and efficiently. Researchers say IgM antibodies show coverage of a wide range of concerns. It can also be given through a nasal spray, while conventional antibody medications require intravenous infusion. Intravenous IgG antibodies must be given in high doses. because most of them are in the blood It has a very limited antiviral effect on the respiratory tract. Nasal delivery allows the dose to be reduced and direct access to the airways and lungs. It can also be administered independently without medical supervision. The researchers said, however, the drug still needs to be tested in humans. To measure the real impact of the drug on the said COVID-19 treatment (https://go.nature.com/34ZYiGV).
E-cigarettes may increase lung risk for coronavirus
Vaping linked to higher rates of COVID-19 in some studies A small new study finds that lung cells exposed to e-cigarette fluids are vulnerable to the spike protein that the coronavirus uses to penetrate the cells. in in vitro experiments The researchers took a sample of cells in the lung line and exposed some of the cells to the fluid used in Juul e-cigs. They then exposed the cells to a harmless virus coated with a protein spike from the lung. corona virus The researchers found higher rates of infection in lung cells treated with e-liquid compared to unexposed cells. According to a report posted Sunday on bioRxiv ahead of peer review. The authors speculate that nicotine may contribute to higher infection rates in cells treated with e-liquid, but they don’t know for sure. “Our results encourage the consideration of vaping as a risk factor for COVID-19,” they said (https://bit.ly/2RwWjXx).
Bots are spreading a lot of false information about COVID-19.
Automated computer programs or “bots” are spreading misinformation about COVID-19 on social media. New research confirms Dr. John Ayers of the University of California, Davis, that bots are easy to spot. “You’re just looking for coordinated behavior, like a Facebook group sharing the same content within seconds,” he said. The study analyzed 299,925 posts in 563 Facebook groups, identifying those that seemed susceptible to bot influence. specially in these groups Identical links were shared at an average time of 4.28 seconds, compared with 4.35 hours for the least bot-influenced group. Researchers reported Monday in JAMA Internal Medicine. They then followed a post that shared a link to a study that found a COVID-19 mask. Where bots are the most influential Posts that share trials are 2.3 times more likely to report false results and 2.5 times more likely to make conspiracy claims than posts shown in the least influenced groups, rather than focusing on bots. Social media companies are still evaluating whether individual posts contain misinformation, Ayers said. ‘Whac-A-Mole,'” he said, adding that the misinformation generated by the bots “May undermine critical health institutions” (https://bit.ly/3gicVui)
Open https://tmsnrt.rs/3c7R3Bl In an external browser for Reuters graphics about the vaccine being developed.
(Reporting by Nancy Lapid and Linda Carroll; Editing by Bill Berkrot)